Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
FDMT

Market Cap: $688.48M

4I

4D Molecular Therapeutics, Inc.

FDMT

NASDAQ (NASDAQ Global Select)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin42.00%

EBITDA Margin-2.01%

EBIT Margin-2.09%

Pre-tax Margin-1.95%

Net Profit Margin-1.95%

Earnings Yield-19.36%

Valuation Multiples

Price / Book2.27

Price / Sales7.48

Price / Earnings-4.84

PEG-0.33

Forward PEG4.10

EV / Sales7.14

EV / EBITDA-3.56

EV / Operating Cash Flow-4.21

EV / Free Cash Flow-4.20

Price / Free Cash Flow-4.39

Price / Operating Cash Flow-5.93

Cash Flow & Capital

Free Cash Flow / Share-$2.23

Operating Cash Flow / Share-$2.22

Free Cash Flow Yield-22.76%

Capex / Revenue0.65%

Capex / Operating Cash Flow-0.38%

Capex / Depreciation0.09

Stock Compensation / Revenue22.18%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio8.03

Quick Ratio8.03

Cash Ratio1.48

Debt / Assets0.08

Debt / Capital0.09

Debt / Equity0.10

Long-Term Debt / Capital0.05

Debt / Market Cap2.84%

Net Debt / EBITDA0.17

Solvency Ratio-2.02

Financial Leverage1.21

Efficiency & Working Capital

Asset Turnover0.19

Fixed Asset Turnover3.18

Inventory Turnover0.00

Receivables Turnover19.95

Payables Turnover4.26

Days Sales Outstanding18.29

Days Inventory Outstanding0

Days Payables Outstanding85.65

Operating Cycle18.29

Cash Conversion Cycle-67.36

Working Capital Turnover0.26

Returns & Quality

Return on Equity-41.33%

Return on Assets-36.37%

Return on Invested Capital-43.77%

ROCE-44.30%

Return on Tangible Assets-36.37%

Operating Return on Assets-39.21%

Income Quality0.87

Tax Burden1.00

Interest Burden0.93

Balance Sheet & Intrinsic Metrics

Enterprise Value$657.32M

Invested Capital$364.21M

Working Capital$335.28M

Tangible Asset Value$407.66M

Net Current Asset Value$298M

Graham Net-Net$3.98

Book Value / Share$5.8

Tangible Book Value / Share$5.8

Cash / Share$5.14

Financial Health Scores

Piotroski Score3

Altman Z-Score2.29

Revenue$92.01M

EBIT$-192.26M

Market Cap$709.39M

Working Capital$335.28M

Retained Earnings$-858M

Total Assets$492.62M

Total Liabilities$84.96M